Company Overview
Arcutis Biotherapeutics, Inc. is a U.S.-based biopharmaceutical company listed on Nasdaq. The company focuses on developing therapies for immune‑mediated diseases and related conditions. Its corporate headquarters are located in Westlake Village, California. Additional information about the company’s programs and corporate strategy can be found on its website at www.arcutis.com .
Recent Trading Performance
| Item | Value |
|---|---|
| Closing price (02:57 AM Central Europe, Friday 23 Feb) | USD 32.20 |
| Price change (24 h) | –2.89 % |
| Market capitalization | USD 4.10 billion |
| Shares outstanding | 125.7 million |
| Volume traded (last 24 h) | USD 53.8 million |
| Year‑to‑date change (since last month end) | +14.72 % |
| 200‑day simple moving average | USD 25.12 |
| 52‑week high | USD 33.30 (20 Oct 2026) |
| 52‑week low | USD 19.30 (19 May 2026) |
24‑Hour Performance of Peer Stocks
| Ticker | 24‑h change | Current price | Market cap | P/E ratio (where available) |
|---|---|---|---|---|
| MAT (Mattel) | –0.24 % | USD 16.94 | USD 4.90 billion | 12.22 |
| UNF (Unifirst /Ma) | +2.76 % | USD 278.99 | USD 4.80 billion | 41.85 |
| PL (Planet Labs PBC) | +2.31 % | USD 13.08 | USD 4.90 billion | – |
| FND (Floor & Decor) | –0.22 % | USD 48.17 | USD 4.80 billion | 21.24 |
| HTFL (Heartflow) | +0.41 % | USD 55.43 | USD 4.80 billion | – |
Summary
During the most recent 24‑hour period ending at 02:57 AM Central Europe, Arcutis Biotherapeutics experienced a 2.89 % decline in share price, closing at USD 32.20. The company’s market capitalization stands at USD 4.10 billion, with 125.7 million shares outstanding. Trading volume for the last day amounted to USD 53.8 million. Despite the short‑term decline, the stock has gained 14.72 % year‑to‑date. The 200‑day simple moving average remains at USD 25.12, and the 52‑week range spans USD 19.30 to USD 33.30. Peer companies in the broader market showed mixed results, with Unifirst /Ma and Planet Labs PBC posting gains, while Mattel and Floor & Decor recorded modest declines.
